Pharmas Market Video Gallery
The FDA approves Effient, Lilly's blood thinner, reports CNBC's Mike Huckman.
More Videos
|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Social Networking's 'Naked' Truth
- Geek Squad V. Gizmodo
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- WPP's Sir Martin Sorrell on the Ad Recession
- Four Things You Should Be Doing Now To Break Out
- Proprietary Trading May Cause October Crash: Investor
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
RSS FEED
» Help
Text Size 
Apr.26
11:35 AM ET
Thursday, 26 Apr 2007
Tamiflu Turnaround
 |
AP |
Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.
The drug has been shown to work in fighting off seasonal and avian flu strains, but there are scattered reports of patient resistance to Tamiflu. Roche responded by quickly expanding its worldwide manufacturing capacity. Soon after, it announced that it could make as much as 400 million courses of Tamiflu per year. (Gilead Sciences [GILD Loading... ()
] discovered Tamiflu and gets royalties on sales from Roche.)But to date, Roche says it has received orders from governments, health agencies and corporations for a total of 215 million courses. So it's scaling back unless or until demand picks up. I suspect that could happen if or when an infected bird is confirmed to have shown up on North American shores.
GlaxoSmithKline [GSK Loading... ()
] makes a much smaller-selling inhalable flu drug called Relenza. And BioCryst Pharmaceuticals [BCRX
Loading...
()
] is testing an injectable antiviral called Peramivir (purr-am-uh-veer).Questions? Comments?
© 2009 CNBC, Inc. All Rights Reserved
MORE FROM CNBC
TOPIC : Pharmaceuticals
COMPANY : BioCryst Pharmaceuticals INC
Data is a real-time snapshot *Data is delayed at least 15 minutes